Comparison between one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization

Ophthalmic Research

Volumn 47, Issue 3, 2012, Pages 135-140

  Niwa, Yuichi ^a   Sawada, Osamu ^a   Miyake, Taichiro ^a   Kakinoki, Masasi ^a   Sawada, Tomoko ^a   Kawamura, Hajime ^a   Ohji, Masahito ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Best corrected visual acuity; Bevacizumab; Central foveal thickness; Myopic choroidal neovascularization

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; EYE EXAMINATION; FEMALE; HUMAN; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA FOVEA; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 80055010244     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000330499     Document Type: Article

References (18)

1. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M: Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110:1297-1305. (Pubitemid 36842462)
2. Secretan M, Kuhn D, Soubrane G, Coscas G: Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997;7:307-316. (Pubitemid 28042043)
3. Johnson DA, Yannuzzi LA, Shakin JL, Lightman DA: Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia. Retina 1998;18:118-124. (Pubitemid 28182775)
4. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia:2-year results of a randomized clinical trial - VIP report No. 3. Ophthalmology 2003;110:667-673.
5. Ohji M, Fujikado T, Kusaka S, Hayashi A, Hosohata J, Ikuno Y, Sawa M, Kubota A, Hashida N, Tano Y: Comparison of three techniques of foveal translocation in patients with subfoveal choroidal neovascularization resulting from age-related macular degeneration. Am J Ophthalmol 2001;132:888-896. (Pubitemid 33122169)
6. Ruiz-Moreno JM, de la Vega C: Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 2001;85:1041-1043. (Pubitemid 32835386)
7. Lai TY, Chan WM, Liu DT, Lam DS: Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009;29:750-756.
8. Monés JM, Amselem L, Serrano A, Garcia M, Hijano M: Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia:12-month results. Eye 2009;23:1275-1280.
9. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS: Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007;91:157-160. (Pubitemid 46202862)
10. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y: Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165. (Pubitemid 46202863)
11. Chan WM, Lai TY, Liu DT, Lam DS: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization:1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150-154.
12. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S: Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: one year outcome. Br J Ophthalmol 2009;93:448-451.
13. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB: Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia:12-month results. Am J Ophthalmol 2009;147:84-93.
14. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y: Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
15. Arias L, Caminal JM, Casas L, Masuet C, Badia MB, Rubio M, Pujol O, Arruga J: A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.
16. Gupta B, Adewoyin T, Patel SK, Sivaprasad S: Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol 2011;95:386-390.
17. Bolz M, Simader C, Ritter M, Ahlers C, Benesch T, Prünte C, Schmidt-Erfurth U: Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:185-189.
18. Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M: Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009;148:396-408.